Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Receivables (2020 - 2023)

SAB Biotherapeutics (SABS) has disclosed Receivables for 4 consecutive years, with $364117.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Receivables fell 96.21% year-over-year to $364117.0, compared with a TTM value of $364117.0 through Jun 2023, down 96.21%, and an annual FY2022 reading of $5.6 million, down 30.69% over the prior year.
  • Receivables was $364117.0 for Q2 2023 at SAB Biotherapeutics, down from $763123.0 in the prior quarter.
  • Across five years, Receivables topped out at $20.6 million in Q4 2020 and bottomed at $364117.0 in Q2 2023.
  • Average Receivables over 4 years is $8.7 million, with a median of $8.8 million recorded in 2021.
  • The sharpest move saw Receivables tumbled 30.69% in 2022, then tumbled 96.21% in 2023.
  • Year by year, Receivables stood at $20.6 million in 2020, then plummeted by 61.04% to $8.0 million in 2021, then crashed by 30.69% to $5.6 million in 2022, then crashed by 93.45% to $364117.0 in 2023.
  • Business Quant data shows Receivables for SABS at $364117.0 in Q2 2023, $763123.0 in Q1 2023, and $5.6 million in Q4 2022.